Which company launched platinib

Pralsetinib (Pralsetinib), also known as BLU-667, is an oral, highly selective and potent RET inhibitor for patients with RET gene fusion-positive non-small cell lung cancer (NSCLC). Behind the development and promotion of this drug is a company with a leading position in the field of biomedicine.

The company that launched platinib is Blueprint Medicines Corporation of the United States, a biopharmaceutical company focused on discovering and developing innovative drugs. Blueprint Medicines is based on precision medicine and focuses on developing treatments for rare and difficult-to-treat cancers. The successful development and launch of Platinib is a reflection of the company's unremitting efforts and innovative spirit.

The development process of Platinib has gone through many years of scientific research and clinical trials. In the clinical trial phase, the drug has demonstrated significant therapeutic effects, providing a new treatment option for patients with RET gene fusion-positive non-small cell lung cancer. After a rigorous approval process, Platinib was finally approved by the U.S. Food and Drug Administration (FDA) in 2020 and has been launched globally, sold under the trade name GAVRETO.

In China, Platinib’s marketing application has also been accepted by the National Medical Products Administration and included in priority review. After the approval process, Platinib was successfully approved for marketing in China, providing new treatment hope for Chinese RET gene fusion-positive non-small cell lung cancer patients. It is also sold under the trade name of Platinib capsules (Pujihua/GAVRETO).